Még nem toboroz
Personnalized Immunotherapy in Patients With Stage III Non-small Cell Lung Cancer
NCT07759492· 2. fázis· Intergroupe Francophone de Cancerologie Thoracique· Forrás
Toboroz
Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse
NCT06625970· 3. fázis· UNICANCER· Forrás
Fut, nem toboroz
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)
NCT06018337· 3. fázis· DualityBio Inc.· Forrás
Toboroz
A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
NCT06149286· 3. fázis· Regeneron Pharmaceuticals· Forrás
Fut, nem toboroz
Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide and Dexamethasone in the Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma
NCT05889221· 2. fázis· Poitiers University Hospital· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
NCT05894239· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
NCT05646862· 3. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & Chemotherapy
NCT05781308· 2. fázis· Intergroupe Francophone de Cancerologie Thoracique· Forrás
Fut, nem toboroz
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
NCT05296798· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction
NCT05255302· 2/3. fázis· Intergroupe Francophone de Cancerologie Thoracique· Forrás
Fut, nem toboroz
Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years).
NCT04751877· 3. fázis· Poitiers University Hospital· Forrás
Fut, nem toboroz
Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS)
NCT04621188· 2. fázis· Intergroupe Francophone de Cancerologie Thoracique· Forrás
Fut, nem toboroz
A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
NCT04640623· 2. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
Study of Trastuzumab Deruxtecan (DS-8201a, T-DXd) versus Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the
Metastatic Setting
2024-516653-44-00· 3. fázis· AstraZeneca AB· Forrás
Fut, nem toboroz
Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer: AIM-HIGH (Adjuvant Intervention in Molecular High Risk Patients)
NCT01817192· 4. fázis· Razor Genomics· Forrás
Toboroz
Randomized phase 3 trial comparing FOLFOX to gemcitabine in metastatic first-line in patients with pancreatic adenocarcinoma and non-fit for FOLFIRINOX (GEMFOX)
NCT04167007· 2/3. fázis· Assistance Publique Hopitaux De Paris· Forrás
Fut, nem toboroz
Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.
NCT04053322· 2. fázis· UNICANCER· Forrás
Fut, nem toboroz
Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy
NCT03977194· 3. fázis· Intergroupe Francophone de Cancerologie Thoracique· Forrás
Fut, nem toboroz
Randomized trial evaluating the addition of nivolumab to cisplatin-radiotherapy combination for treatment of cancers of the head and neck
2024-513206-65-00· 3. fázis· Groupe Oncologie Radiotherapie Tete Cou· Forrás
Lezárult
LEAn Body Mass Normalization of OXaliplatin Based Chemotherapy
NCT03255434· 2. fázis· Institut du Cancer de Montpellier - Val d'Aurelle· Forrás
Lezárult
PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection
NCT03079011· 3. fázis· UNICANCER· Forrás
Toboroz
Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver
NCT02885753· 3. fázis· Federation Francophone de Cancerologie Digestive· Forrás
Fut, nem toboroz
Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy
NCT02889523· 1/2. fázis· The Lymphoma Academic Research Organisation· Forrás
Fut, nem toboroz
PRODIGE 34 - ADAGE: Randomised phase III study evaluating adjuvant chemotherapy after resection of stage III colon adenocarcinoma in patients aged 70 and older
NCT02355379· 2. fázis· Fondation Franc.Cancerologie Digestive· Forrás